Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Efficacy and safety of first-line orelabrutinib combined with obinutuzumab (With or Without Bendamustine) in high-risk marginal zone lymphoma: Results from the orchid study

View Full Paper
Ask AI
Bookmark
Share

Authors

GWGuolin WuDFDandan FanHSHao Song

Discussion

Loading...

Member takes

Overview

Phase 2 study shows 100% complete response in high-risk marginal zone lymphoma with orelabrutinib and obinutuzumab, implying strong therapeutic potential.

Key Points

  • Orelabrutinib and obinutuzumab yielded a complete response rate of 100% at interim efficacy assessment, indicating high effectiveness against high-risk marginal zone lymphoma.
  • Among 20 patients, the estimated 6-month progression-free survival was 90%, suggesting significant delays in disease progression with this regimen.
  • Patients received either the orelabrutinib-obinutuzumab combination or the combination with bendamustine, both displayed similar high response rates and encouraging safety profiles.
  • Safety assessments reported no severe adverse events, with manageable toxicity including mild infections and fatigue, underscoring a favorable treatment safety profile.

Cite This Study

Wu et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da19https://doi.org/10.1182/blood-2025-3597
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Preliminary analysis of orelabrutinib combined with obinutuzumab in the treatment of marginal zone lymphoma (Orion Study)2025
  2. 2Efficacy, safety, and NGS analysis of orelabrutinib combined with obinutuzumab in untreated marginal zone lymphoma2025
  3. 3Preliminary study results of orelabrutinib in combination with rituximab for treatment-Naïve marginal zone lymphoma: A prospective single-arm clinical trial2025 · 1 citations
  4. 4Orelabrutinib combined with bendamustine-rituximab or obinutuzumab followed by orelabrutinib maintenance in untreated marginal zone lymphoma (Optimize): A multicenter, single-arm, phase II study2025 · 1 citations
  5. 5Real-world efficacy and safety of orelabrutinib-based regimens in the treatment of marginal zone lymphoma2025